Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in prostate cancer
- New trial
Prostate cancer
4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy
This trial evaluates whether 4-aminopyridine can accelerate recovery from peripheral nerve injuries sustained during surgery for localized prostate cancer, comparing an investigational potassium channel blocker…
NCT03701581 - Trial result
Prostate cancer
Elective Nodal Radiotherapy Outperforms MDT in Oligorecurrent Nodal Prostate Cancer
In the phase 2 PEACE V-STORM trial of 190 evaluable patients with PET-detected pelvic nodal recurrences, elective nodal radiotherapy (ENRT) with androgen deprivation achieved a 4-year metastasis-free survival of 76%…
- Trial result
Prostate cancer
Enzalutamide Plus ADT Shows Prognostic Benefit Tied to PSA Response in mHSPC
In this secondary analysis of the ARCHES phase 3 trial with 1,150 men, enzalutamide added to androgen deprivation therapy (ADT) improved radiographic progression-free and overall survival across PSA subgroups.…
- New trial
Prostate cancer
Phase II Study: Sequential BATZEN and ZENZA Therapy in Metastatic CRPC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is testing whether an initial phase of testosterone plus ZEN-3694 (BATZEN) followed by dose-escalated ZEN-3694 with enzalutamide (ZENZA) can reduce tumor…
NCT06922318 - New trial
Prostate cancer
Phase II Trial: Evaluating Enhertu in HER2+ mCRPC
Washington D.C. Veterans Affairs Medical Center is assessing the efficacy and safety of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive metastatic castration-resistant prostate cancer patients who have…
NCT06610825 - New trial
Prostate cancer
Phase III Study: Adjuvant Saruparib with RT + ADT in BRCA-Mutant High-Risk Prostate Cancer
AstraZeneca is investigating whether adding the PARP1 inhibitor saruparib (AZD5305) to standard radiation therapy and androgen deprivation therapy—with or without abiraterone—improves metastases-free survival in…
NCT06952803 - Trial result
Prostate cancer
Enzalutamide Plus Venetoclax Shows Early Signals of Activity in mCRPC
In this phase Ib trial for metastatic castration-resistant prostate cancer, enzalutamide was combined with escalating doses of venetoclax (up to 800 mg/day) in a 3+3 design with no dose-limiting toxicities observed;…
- New trial
Prostate cancer
Phase III RCT Evaluates RALP with SAFE Nerve Preservation Guided by Micro-Ultrasound
This randomized trial at Mount Sinai compares standard robotic-assisted laparoscopic prostatectomy to a variant using SALINE Assisted Fascial Engorgement (SAFE) with high-resolution micro-ultrasound guidance, aiming…
NCT06945315 - New trial
Prostate cancer
Open-label Study on Lutetium-177 Vipivotide Tetraxetan Safety and Dosimetry in mCRPC
Novartis is investigating how moderate to severe renal impairment affects the biodistribution, dosimetry, and safety of Lutetium-177 vipivotide tetraxetan in progressive PSMA-positive mCRPC patients, including…
NCT06004661
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.